Furthermore, based on recent studies reporting cell cycle-independent function of CDK1 in coupling proliferation with activation of eIF4E protein synthesis38 via its ability to phosphorylate translational regulators/repressors including eIF4BP139, LARP1 involved in regulating 5’ Terminal OligoPyrimidine (5′ TOP) motif-containing mRNAs40,41, RPS342, we envision employing this preclinical IBC model to evaluate the efficacy of CDK1 inhibitors alone and in combination with TKIs and other chemotherapeutics. Here, CDK1 is linked to inflammatory breast carcinoma.